Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Limited (KIMS) has released its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026, accompanied by a Reasonable Assurance Report from Brahmayya & Co. Chartered Accountants. The report details KIMS's performance across key environmental, social, and governance (ESG) indicators, including greenhouse gas emissions, water and energy consumption, waste management, employee wellbeing, gender diversity, and customer relations, all prepared in accordance with SEBI regulations and the Industry Standards Forum’s BRSR Core Reporting Standard. Brahmayya & Co. provided a reasonable assurance opinion, signifying a high level of confidence in the reported data, though the assurance engagement was limited to specific “Identified Sustainability Information” and does not cover all aspects of the BRSR or internal controls. The report, bearing UDIN 26222320JBLDLV1577, is intended for the Board of Directors and stakeholders.

Krishna Hospitals announced a 14% increase in inpatient volume and a 26.6% rise in outpatient volume for the first quarter of fiscal year 2024, alongside a 9.7% increase in average revenue per outpatient and a 14% rise in average revenue per inpatient. The company also highlighted several successful medical procedures and milestones across its various hospitals, including kidney transplants, robotic surgeries, and complex interventions for rare conditions, and the addition of a new hospital in Palakkad, Kerala. Krishna Hospitals reported a healthy topline and bottom line, and plans to add more than 1,300 beds through upcoming projects.

CARE Ratings Ltd.’s monitoring report, released recently, assesses the deployment of proceeds from a public offering by Krishna Diagnostics Pvt. Ltd. as of June 30, 2026. The report indicates Rs 351.45 crore was allocated for general corporate purposes, with Rs 20 crore and Rs 2.00 crore invested in KIMS Hospitals Bengaluru and Chalasani Hospitals, respectively, and Rs 22 crore used for salaries and consultant fees. A significant portion, Rs 413.51 crore, remains temporarily invested in liquid instruments like ICICI Prudential Money Market Fund and Kotak Mahindra Bank accounts. While the report suggests funds are being deployed in accordance with the placement document, which allows up to 25% for general corporate purposes, it notes that these funds have been commingled with regular business funds, potentially complicating tracking. The monitoring agency emphasizes it relied on information provided by Krishna Diagnostics and disclaims any legal liability.

Krishna Institute of Medical Sciences Limited reported no deviation or variation in the utilisation of Rs 1500 crore raised through a Qualified Institutional Placement from the objects stated in the Placement Document dated June 19, 2026, according to a filing with the Bombay Stock Exchange and National Stock Exchange on August 3, 2026. The company’s Audit Committee noted the NIL deviation during a meeting on August 3, 2026, and CARE Ratings Limited serves as the monitoring agency.

Krishna Institute of Medical Sci. will hold a meeting of the Board of Directors of the Company on 3 August 2026.

The committee approved the opening of the issue on 16 June 2026. The floor price of Rs 771.73 per equity share is at a discount of 0.83% to the scrip's previous closing price of Rs 778.15 on the BSE. The company may offer a discount of not more than 5% on the floor price for the issue. The issue price will be determined in consultation with the bookrunning lead managers appointed for the issue. The Finance & Investment Committee is scheduled to meet on 19 June 2026 to consider and approve the issue price, including any discount thereto, in accordance with SEBI regulations. Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana and Andhra Pradesh, providing multidisciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at an affordable cost. The company's consolidated net profit declined 58.25% to Rs 42.50 crore despite a 34.85% increase in revenue to Rs 1,074.60 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live

Krishna Institute of Medical Sci. announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 July 2026.

Each warrant is convertible into one equity share within 18 months from the date of allotment. Of the total proposed issuance, 64.19 lakh warrants aggregating Rs 500 crore will be allotted to promoters Dr. Abhinay Bollineni and Mr. Advik Bollineni, while 12.84 lakh warrants aggregating Rs 100 crore will be allotted to promoter-group entity Bharas Ventures LLP. The proposal remains subject to shareholder approval and other regulatory clearances. The company has also scheduled an extra-ordinary general meeting (EGM) for 09 July 2026 to seek shareholder consent for the same. Assuming 100% conversion of warrants, shareholding of Dr. Abhinay Bollineni will rise to 0.84% from 0.06% currently, and that of Adwik Bollineni will climb to 0.80% from 0.01%. Bharas Ventures LLP will own 0.31% stake in the company post warrant conversion. Bharas Ventures is a limited liability partnership between the company's two promoters, viz., Dr. Bhaskara Rao Bollineni and Ms. Rajyasri Bollineni. Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana and Andhra Pradesh, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. The company's consolidated net profit declined 58.25% to Rs 42.50 crore despite a 34.85% increase in revenue to Rs 1,074.60 crore in Q4 FY26 over Q4 FY25. The scrip fell 2.88% to end at Rs 787.10 on the BSE on Friday. Powered by Capital Market - Live

The proposed fund raise may involve equity shares, fully convertible warrants, convertible or non-convertible securities, or a combination thereof through permissible modes, including a preferential issue on a private placement basis or any other approved route. Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana and Andhra Pradesh, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. On consolidated basis, the company's net profit declined 58.25% to Rs 42.5 crore in Q4 FY26 from with Rs 101.8 crore in Q4 FY25. Revenue from operations Revenue from operations increased 34.85% YoY to Rs 1,074.6 crore in Q4 FY26.Powered by Capital Market - Live

Krishna Institute of Medical Sci. will hold a meeting of the Board of Directors of the Company on 13 June 2026.